According to a post hoc analysis of the SOLOIST-WHF study, the use of Inpefa (sotagliflozin) for heart failure (HF) was shown to reduce the 90-day risk of cardiovascular (CV) mortality or hospital re-admission compared to placebo.
The study also found that initiating Inpefa before discharge in patients hospitalised for worsening HF drastically decreased CV deaths and HF events. Inpefa acts by inhibiting sodium-glucose cotransporter types 2 and 1 (SGLT2 and SGLT1). GlobalData believes that this study could be of high clinical value to cardiologists looking to find an optimal treatment of choice for patients, which may bolster the current use of the drug among patients with HF.
SOLOIST-WHF is the first large randomised controlled study to demonstrate that the initiation of SGLT inhibitors in acute HF in stabilised patients before hospital discharge or soon after is safe and effective. Key opinion leaders interviewed by GlobalData emphasised that SGLT2s are taking precedence over established older classes because they are effective, and physicians don’t have to be wary of major side effects when discharging patients from the hospital.
The incidence of acute HF is rising and represents a huge financial burden on the global healthcare systems due to resources and costs associated with the hospitalisation and the highly likely re-admission of a patient. Developing an evidence-based therapy for the treatment of acute HF represents a huge opportunity.
Lexicon Pharmaceuticals’ Inpefa was approved in May 2023 for HF and has had to compete with already well-established SGLT2 inhibitors Forxiga (dapagliflozin) and Jardiance (empagliflozin). The widespread use of generic HF drugs also continues to make it difficult for high-priced branded therapies to fully penetrate the market. Data from the post hoc analysis potentially shows clinical and commercial benefits of Inpefa over other SGLT2 inhibitors.
Lexicon is a biopharmaceutical company that focuses on the discovery, development and commercialisation of innovative treatments for human diseases.